The five cardiovascular outcome trials (CVOT) conducted in patients with type 2 diabetes mellitus so far have shown that renal sodium-glucose cotransporters two inhibitors (SGLT2i) are cardiovascular (CV) safe [1–5]. This finding paved the way for their use in patients with type 2, and even type 1, diabetes to reduce the HbA1c by 0.5 to 1.5%, depending on the baseline values. However, CVOT demonstrated a CV benefits of SGLT2i well beyond their antidiabetic effect.
